Stay updated with breaking news from Orally Administered. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data from the phase 2a trial showed 25.7% of patients with UC demonstrated endoscopic improvement and 45.7% achieved clinical response after week 12.
A look at the arguments for and against the use of medicinal cannabis
Researchers compare the pharmacokinetics and pharmacodynamics of oral Δ9-tetrahydrocannabinol-dominant and cannabidiol-dominant cannabis extracts that contained the same Δ9-THC dose (20 mg).
– On track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer – – Enrolling...
25.01.2022 - – End of Phase 2 Meeting with FDA Provides Pathway to NDA Submission for MAT2203 Following Confirmatory Data to be Generated in an Additional Cohort; Cohort 5 in Ongoing EnACT Trial – – Cohort 4 of EnACT (all oral induction regimen) Underway With ... Seite 1